Oncology
1 drug is in development for Rectal Cancer.
- Companies
- 1
- Clinical trials
- 24
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Rectal Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| CTX-009 | Compass Therapeutics, Inc. (CMPX) |
About this indication
Rectal Cancer context
Oncology·MeSH: Rectal Neoplasms (D012004)
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Rectal Cancer?
BioSniper tracks 1 drug in development for Rectal Cancer across 1 company.
How many clinical trials target Rectal Cancer?
There are 24 clinical trials targeting Rectal Cancer tracked by BioSniper.
What is the prevalence of Rectal Cancer?
The estimated prevalence of Rectal Cancer is approximately 135.0 per 100,000 population.